Cantitate/Preț
Produs
Total produse
Vezi coșul
Fluoropyrimidines in Cancer Therapy de Youcef M. Rustum

Fluoropyrimidines in Cancer Therapy: Cancer Drug Discovery and Development

Editat de Youcef M. Rustum
en Limba Engleză Hardback – 2 dec 2002
Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 75605 lei  6-8 săpt.
  Humana Press Inc. – 19 noi 2010 75605 lei  6-8 săpt.
Hardback (1) 106790 lei  6-8 săpt.
  Humana Press Inc. – 2 dec 2002 106790 lei  6-8 săpt.

Din seria Cancer Drug Discovery and Development

  • 5% CNS Cancer: Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches
    Preț: 141903 lei
  • 5% Developments in T Cell Based Cancer Immunotherapies
    Preț: 106636 lei
  • 5% mTOR Pathway and mTOR Inhibitors in Cancer Therapy
    Preț: 136204 lei
  • 5% Antiangiogenic Agents in Cancer Therapy
    Preț: 137019 lei
  • 5% Tumor Models in Cancer Research
    Preț: 139720 lei
  • 5% Telomeres and Telomerase in Cancer
    Preț: 131674 lei
  • 5% Gene Therapy for Cancer
    Preț: 138491 lei
  • 5% Proteasome Inhibitors in Cancer Therapy
    Preț: 107142 lei
  • 5% Oncogene-Directed Therapies
    Preț: 108357 lei
  • 24% Protein Tyrosine Kinases: From Inhibitors to Useful Drugs
    Preț: 103759 lei
  • 5% Cancer Chemoprevention: Volume 2: Strategies for Cancer Chemoprevention
    Preț: 141073 lei
  • 5% Apoptosis, Senescence and Cancer
    Preț: 135078 lei
  • 5% Bioinformatics in Cancer and Cancer Therapy
    Preț: 136378 lei
  • 5% Bone Metastasis
    Preț: 107127 lei
  • 5% Nitric Oxide (NO) and Cancer: Prognosis, Prevention, and Therapy
    Preț: 137437 lei
  • 5% Tumor Suppressor Genes in Human Cancer
    Preț: 137556 lei
  • 5% Platinum-Based Drugs in Cancer Therapy
    Preț: 75252 lei
  • 5% Regional Cancer Therapy
    Preț: 138402 lei
  • 5% Checkpoint Controls and Targets in Cancer Therapy
    Preț: 106825 lei
  • 5% Antifolate Drugs in Cancer Therapy
    Preț: 137999 lei
  • 5% Transforming Growth Factor-Beta in Cancer Therapy, Volume II: Cancer Treatment and Therapy
    Preț: 136582 lei
  • 5% Transforming Growth Factor-Beta in Cancer Therapy, Volume I: Basic and Clinical Biology
    Preț: 140566 lei
  • 5% Farnesyltransferase Inhibitors in Cancer Therapy
    Preț: 106492 lei
  • 5% Supportive Care in Cancer Therapy
    Preț: 98218 lei
  • 5% Nucleic Acid Therapeutics in Cancer
    Preț: 70030 lei
  • 5% Stem Cells and Cancer
    Preț: 133176 lei
  • 5% EGFR Signaling Networks in Cancer Therapy
    Preț: 129740 lei
  • 5% Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics
    Preț: 108197 lei
  • 5% Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
    Preț: 137874 lei
  • 5% Hormone Therapy in Breast and Prostate Cancer
    Preț: 106878 lei
  • 5% Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications
    Preț: 131776 lei
  • 5% The Oncogenomics Handbook
    Preț: 140933 lei
  • 5% Macromolecular Anticancer Therapeutics
    Preț: 186600 lei
  • 5% Histone Deacetylases: Transcriptional Regulation and Other Cellular Functions
    Preț: 136467 lei
  • 5% Cancer Drug Resistance
    Preț: 138436 lei
  • 5% Matrix Metalloproteinase Inhibitors in Cancer Therapy
    Preț: 105859 lei
  • 5% In Vivo Imaging of Cancer Therapy
    Preț: 99058 lei
  • 5% The Tumor Microenvironment
    Preț: 138840 lei
  • 5% Camptothecins in Cancer Therapy
    Preț: 137471 lei
  • 5% Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins
    Preț: 75781 lei
  • 5% Cancer Proteomics: From Bench to Bedside
    Preț: 131172 lei
  • 5% Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
    Preț: 133176 lei
  • 5% COX-2 Blockade in Cancer Prevention and Therapy
    Preț: 107093 lei
  • 5% Cytokines in the Genesis and Treatment of Cancer
    Preț: 138611 lei

Preț: 106790 lei

Preț vechi: 112411 lei
-5% Nou

Puncte Express: 1602
Preț estimativ în valută:
20438€ • 21561$ • 17032£

Carte tipărită la comandă

Livrare economică 02-16 ianuarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780896039568
ISBN-10: 0896039560
Pagini: 326
Ilustrații: XII, 326 p.
Dimensiuni: 178 x 254 x 21 mm
Greutate: 0.81 kg
Ediția:2003
Editura: Humana Press Inc.
Colecția Humana
Seria Cancer Drug Discovery and Development

Locul publicării:Totowa, NJ, United States

Public țintă

Professional/practitioner

Cuprins

1 Relative Role of 5-Fluorouracil Activation and Inactivation Pathways on its Cytotoxic Effects: Preclinical and Clinical Modulation.- 2 Dihydropyrimidine Dehydrogenase and Treatment by Fluoropyrimidines: Past and Future Directions.- 3 Biochemical Bases of the 5-Fluorouracil—Folinic Acid Interaction and of its Limitations: A Retrospective Analysis.- 4 Molecular Mechanisms Regulating the Expression of Thymidylate Synthase.- 5 Regulation of Thymidylate Synthase Gene Expression and Drug Response: Posttranscriptional Regulation and Cell Population Density.- 6 Death Receptor Signaling in the Mechanism of 5-Fluorouracil Action.- 7 Circadian Rhythms in 5-Fluorouracil Pharmacology and Therapeutic Applications.- 8 Relevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other Agents.- 9 Noninvasive Studies of Fluoropyrimidines.- 10 Comparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems: Role of Leucovorin and Dihydropyrimidine Dehydrogenase Inhibitors.- 11 Bimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal Cancer.- 12 Review on the Combination of Systemic and Locoregional Treatment for Colorectal Liver Metastases.- 13 Fluoropyrimidines in Advanced Colorectal Cancer: A Review of Six Consecutive Meta-Analyses.- 14 The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer.- 15 Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer: The NSABP Experience.- 16 Clinical Trials of UFT Leucovorin in Gastrointestinal Malignancies.- 17 The Development of Oral UFT with and without Leucovorin.- 18 UFT in Elderly Patients with Colorectal Cancer.- 19 Clinical Trials of the Eniluracil/5-Fluorouracil Combination.- 20 Discovery andPreclinical Pharmacology of Capecitabine.- 21 Capecitabine, A Tumor-Targeting Oral Fluoropyrimidine: Molecular Rationale and Clinical Validation.- 22 Capecitabine: A Rationally Developed Anticancer Drug.- 23 Preclinical and Clinical Practice of S-1 in Japan.- 24 Preclinical and Clinical Practice of Low-Dose FP Therapy in Japan: Japanese Use of Low-Dose FP Therapy.

Textul de pe ultima copertă

Although the action of the standard chemotherapeutic agent for the treatment of advanced colorectal cancer (5-fluorouracil or 5-FU) was improved significantly by combining it with leucovorin (LV), the improved response rate was associated with significant side-effects in approximately thirty percent of patients. In Fluoropyrimidines in Cancer Therapy, leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU, with and without LV and its prodrugs, in the treatment of colorectal cancer. Among the combination agents considered are Orzel (UFT/LV), 5-FU/Eniluracil (5-FU/EU), capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on the historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.
Authoritative and integrative, Fluoropyrimidines in Cancer Therapy summarizes the latest preclinical and clinical experiences using fluoropyrimidines to treat colorectal cancer, delineates the underlying mechanisms and choices for therapy, describes the ongoing search to identify ever more effective and selective agents with novel mechanisms of action, and details the development of new mechanism-based combination therapies.

Caracteristici

Includes supplementary material: sn.pub/extras